Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in metastatic colorectal cancer (CA180048)

Trial Profile

Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in metastatic colorectal cancer (CA180048)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Dasatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 09 Mar 2017 Results (n=77) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 07 Jan 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top